Therapy Areas: Autoimmune
SetPoint Raises USD 30m Financing for Development of Bioelectronic Medicine Platform
29 August 2017 - - US-based bioelectronic therapy developer SetPoint Medical has secured USD30 m in Series D equity financing, the company said.
The Series D financing will provide SetPoint with funding to further advance the clinical development of its bioelectronic therapy for chronic, debilitating inflammatory diseases.
This Series D round includes participation from SetPoint's existing investors, including NEA, Morgenthaler, Medtronic, Boston Scientific, Topspin, Action Potential Venture Capital, and others.
SetPoint is developing a novel proprietary bioelectronic medicine platform using a small implanted device that stimulates the vagus nerve to activate the body's natural inflammatory reflex and produces a systemic anti-inflammatory effect.
The emerging field of bioelectronic medicine aims to address unmet patient needs by delivering targeted digital doses to modulate physiological circuits to treat diseases historically treated with drugs.
SetPoint Medical is a privately held biomedical technology company dedicated to treating patients with debilitating inflammatory diseases using bioelectronic therapy. Its approach is intended to offer patients and providers an alternative treatment for rheumatoid arthritis and other chronic inflammatory diseases with less risk and cost than drug therapy.
Login
Username:

Password: